Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
Abstract
(Abstracted from N Engl J Med 2019;381:2391–2402) The standard treatment for newly diagnosed advanced epithelial ovarian cancer involves cytoreductive surgery and platinum-taxane combination chemotherapy. Unfortunately, recurrence occurs in up to 85% of patients after completing this chemotherapy regimen.